Skip to content
sellWeak cluster of 310b5-1 plan

Atul Pande sold $192k of IMVT

director at Immunovant, Inc.. 6,000 shares at an average of $32.00, traded May 20, 2026, filed May 20, 2026.

Warning score
7
Value
$192k
6,000 shares
Holdings after
116,731
-5% from before
From 52-week low
+152%
low $14.10, close $35.56
From 52-week high
0%
high $35.56, as of May 20, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $192k at market
    +12
  • Share of holdings sold
    Sold 4.9% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IMVTOct 9, 2026 · close 30.47
Since filing May 20, 2026: -14.3%SPY +5.5% · excess -19.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001643071-26-000004, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 20, 2026MOption exercise
Common Stock10b5-1
+6,000$8.43$51k122,731May 20, 2026
May 20, 2026SOpen-market sale
Common Stock10b5-1
-6,000$32.00$192k116,731May 20, 2026
May 20, 2026MOption exercise
Stock Option (right to buy)derivative10b5-1
-6,000$0.00$0270,252May 20, 2026

Related signals

Other insiders at Immunovant, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
43Moderate
IMVTsell 4
Immunovant, Inc.
Melanie Gloria
Chief Operating Officer
$72k
2,241 shares
-1%
40Moderate
IMVTsell 4
Immunovant, Inc.
Jay S Stout
Chief Technology Officer
$122k
3,809 shares
-2%
36Weak
IMVTsell 4
Immunovant, Inc.
Christopher Van Tuyl
Chief Legal Officer
$43k
1,327 shares
-1%
35Weak
IMVTsell 4
Immunovant, Inc.
Eric Venker
Chief Executive Officer
$120k
3,506 shares
-1%
40Moderate
IMVTsell 4
Immunovant, Inc.
Christopher Van Tuyl
Chief Legal Officer
$103k
2,846 shares
-2%
0Weak
IMVTsell 210b5-1
Immunovant, Inc.
Atul Pande
director
$65k
1,500 shares
-1%
39Weak
IMVTsell 2
Immunovant, Inc.
Melanie Gloria
Chief Operating Officer
$135k
3,056 shares
-1%
50Moderate
IMVTsell 3
Immunovant, Inc.
Tiago Girao
Chief Financial Officer
$263k
6,798 shares
-3%
2Weak
IMVTsell 310b5-1
Immunovant, Inc.
Atul Pande
director
$60k
1,500 shares
-1%
40Moderate
IMVTsell 3
Immunovant, Inc.
Jay S Stout
Chief Technology Officer
$111k
2,857 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Atul Pande sold $192k of IMVT | InsiderTell